Figure 1: Responder rates (SeDBP<90 mmHg or 10 mmHg reduction in SeDBP) in groups treated with olmesartan (OM) and olmesartan medoxomil/hydrochlorothiazide (OM/HCTZ). Responder rates increase after switching from OM to OM/HCTZ, progressively increasing with up-titration of OM/HCTZ. Elaborated from (6).